Comparative activity of β-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA β-lactamases

Chemotherapy

Volumn 50, Issue 1, 2004, Pages 31-34

  Bert, Frédéric ^a   Branger, Catherine ^a   Lambert Zechovsky, Nicole ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Lactam agents; Lactamases; Carbenicillinases; In vitro activity; Oxacillinases; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFPIROME; CEFSULODIN; CEFTAZIDIME; CLAVULANIC ACID; PIPERACILLIN; TAZOBACTAM; TICARCILLIN;

ARTICLE; BACTERIAL STRAIN; COMPARATIVE STUDY; DILUTION; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME ANALYSIS; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CARRIER PROTEINS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PENICILLINASE; PSEUDOMONAS AERUGINOSA;

EID: 1842862848     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077282     Document Type: Article

References (14)

1. Péchère JC, Köhler T: Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 1999;5:S15-S18.
2. Chen HY, Yuan M, Livermore DM: Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995;43:300-309.
3. Cavallo JD, Fabre R, Leblanc F, Nicolas-Chanoine MH, Thabaut A; Groupe d'Etude de la Résistance de Pseudomonas aeruginosa aux Betalactamines: Antibiotic susceptibility and mechanisms of β-lactam resistance in 1310 strains of Pseudomonas aeruginosa: A French multicentre study (1996). J Antimicrob Chemother 2000;46:133-136.
4. Bonfiglio G, Marchetti F: In vitro activity of ceftazidime, cefepime and imipenem on 1005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Chemotherapy 2000;46:229-234.
5. Sanschagrin F, Couture F, Levesque RC: Primary structure of OXA-3 and phylogeny of oxacillin-hydrolyzing class D β-lactamases. Antimicrob Agents Chemother 1995;39:887-893.
6. Naas T, Nordmann P: OXA-type beta-lactamases. Curr Pharm Design 1999;5:865-879.
7. Aubert D, Poirel L, Ben Ali A, Goldstein FW, Nordmann P: OXA-35 is an OXA-10-related β-lactamase from Pseudomonas aeruginosa. J Antimicrob Chemother 2001;48:717-721.
8. Bert F, Branger C, Lambert-Zechovsky N: Characterization of PSE and OXA β-lactamases from Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 2002;50:11-18.
9. 9NCCLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A5. Wayne, NCCLS, 2001.
10. Comité de l'Antibiogramme de la Société Française de Microbiologie: Communiqué 2002. Paris, Société Française de Microbiologie, 2002.
11. Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM, Nordmann P: Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1615-1620.
12. Poole K, Gotoh N, Tsujimot H, Zhao QX, Wada A, Yamasaki T, Neshat S, Yamagiski J, Li XZ, Nishino T: Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996;21:713-724.
13. Ziha-Zarifi I, Llanes C, Köhler T, Péchère JC, Plesiat P: In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexAMexB-OprM. Antimicrob Agents Chemother 1999;43:287-291.
14. McLaughlin JC, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, Pfaller MA: In-vitro activity of five β-lactam/β-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1994;33:223-230.